Parikh, Neal S. http://orcid.org/0000-0002-8802-2380
Jesudian, Arun
Kamel, Hooman
Hanley, Daniel F.
Ziai, Wendy C.
Murthy, Santosh B.
Hanley, D. F.
Butcher, K.
Davis, S.
Gregson, B.
Lees, K. R.
Lyden, P.
Mayer, S.
Muir, K.
Steiner, T.
,
Funding for this research was provided by:
Leon Levy Foundation
New York State Department of Health Empire Clinical Research Investigator Program
Florence Gould Foundation
The Society of Interventional Radiology Foundation
National Institute of Neurological Disorders and Stroke (R01NS097443, U01NS095869, K23NS105948)
Michael Goldberg Research Fund
National Institutes of Health (1U01NS080824, U24TR001609, U01NS080824)
Article History
Received: 21 May 2020
Accepted: 6 August 2020
First Online: 17 August 2020
Conflicts of interest
: Dr. Parikh, Dr. Jesudian, Dr. Murthy: none. Hooman Kamel serves as the co-PI for the NIH-funded ARCADIA trial which receives in-kind study drug from the BMS-Pfizer Alliance and in-kind study assays from Roche Diagnostics, serves as a steering committee member of Medtronic’s Stroke AF trial (uncompensated), serves on an endpoint adjudication committee for a trial of empagliflozin for Boehringer Ingelheim, and has served on an advisory board for Roivant Sciences related to Factor XI inhibition. Dr. Hanley reports personal fees from Op2Lysis, personal fees from BrainScope, personal fees from Neurotrope, and non-financial support from Genentech outside the submitted work. Dr, Ziai receives consulting fees from C.R. Bard, Inc., and Portola Pharmaceuticals, Inc., outside of the area of work commented on here.
: Trials included in the VISTA-ICH cohort were performed with institutional review board and/or regulatory approval, and our analysis was approved by the Weill Cornell Medicine Institutional Review Board.